“Evidence-based clinical practice is an approach to decision-making in which the clinician uses the best evidence available, in consultation with the patient, to decide upon the option which suits that patient best”.
The text that follows in this Dispensary Program is merely a suggestion of the potential therapeutic or prophylactic value based on best available evidence at the time, professional collective anecdotal experience and safety profile after comprehensive research and long term traditional use. The FDA, EFSA, TGA, SA DoH, or MCC has approved none of the statements or product indications made.
In some cases, the products as whole or the individual ingredients are supported by well-conducted clinical trials and systematic reviews. In cases where a combination of ingredients creates a unique product where no research on the product as whole is available, careful attention has been given to each added isolate and or herb extract to theoretically augment therapeutic effect, whilst avoiding known herb interactions or toxicity.
Although the majority of the research is drawn from peer reviewed DB RCT's several of the published studies used to support the “Primary & Secondary Indications” and “Proposed mechanisms of action” are based on animal models. The clinical therapeutic value thereof cannot be considered established but merely proposed as a probable outcome, and in the light of traditional use or low risk profiles, may be indicated in certain conditions as complementary medicine. The safety profile and monograph of herb ingredients are readily available from reputable online databases, such as the British Herbal Pharmacopoeia, Australian TGA List of Substances; WHO Monographs on Selected Medicinal Plants, ESCOP Monographs, and other national & international monographs and peer reviewed literature.
Each therapeutic indication should be questioned by the prescribing practitioner utilizing the research available on dispensary manual, pharmacopoeias and reputable online databases. Practitioners are to use rational clinical prescribing, taking into account the patient's unique presentation, the risk stratification of disease and the safety profile of the proposed herbal medicine, and whether conventional medicine with related clinical research is more appropriate. The products are listed with both the MCC and the Australian Therapeutic Goods Administration (TGA) and are manufactured under stringent GMP.
Our products are supplied exclusively to qualified practitioners and dispensed under prescription; they are not distributed to health stores, retail outlets or the general public.
 Gray JAM. 1997. Evidence-based healthcare: how to make health policy and management decisions. London: Churchill Livingstone.
Copyright: All content contained in this dispensary program, such as text, graphics, logos, button icons and images is the property of Wings Herbal Synergy or its content suppliers and protected by South African and international copyright laws. The selection, arrangement, and presentation of all materials contained in this program and the overall design of this program is the exclusive property of Wings Herbal Synergy cc and again is protected by South African and international copyright laws.